Long-Term Treatment Results for Ovarian Tumors with Malignant Effusion in Seven Dogs

Abstract

Surgery and platinum-based chemotherapy are highly efficacious for treating advanced ovarian cancers in humans, but their efficacy is less known in dogs. We evaluated the long-term treatment outcomes of seven dogs with malignant ovarian tumors with malignant abdominal effusion. Ovariohysterectomies (OVHs) were performed on all dogs; four had ovarian adenocarcinoma (AC) with gross dissemination in the peritoneum (two with pleural effusion), and three had a granulosa cell tumor (GCT) with no gross dissemination in the peritoneal cavity, although one showed pleural effusion. Effusion resolved after the OVH in all dogs. Six dogs (three ACs, three GCTs) received postoperative IV carboplatin therapy. Two dogs with GCT had no postoperative recurrence or metastasis, and one dog with GCT had recurrence 1811 days postoperatively. All dogs with AC developed recurrent effusion 171–584 days postoperatively, which resolved after intracavitary administration of cisplatin or carboplatin, with a subsequent disease-free interval of 155–368 days. Overall survival was longer for dogs with GCTs (822–1840 days) than for those with ACs (617–841 days). These results suggest that dogs with ovarian tumors with malignant effusion can survive relatively long after platinum-based chemotherapy in addition to OVH, with a more favorable prognosis for GCT than AC.

Immunohistochemical features of canine ovarian papillary adenocarcinoma and utility of cell block technique for detecting neoplastic cells in body cavity effusions

“…In the present study, 3 cases of ovarian papillary adenocarcinoma presented with ascites and pleural effusion, which resolved after ovariectomy. Similar conditions were also reported in previous canine cases of ovarian papillary adenocarcinoma [ 12 , 13 , 14 , 21 ]. The phenomena are thought to be associated with Meigs or pseudo-Meigs syndrome in veterinary medicine.…”

“…However, these markers have not been examined in canine ovarian papillary adenocarcinoma. Dogs with ovarian papillary adenocarcinoma occasionally present with ascites and/or pleural effusions [4,12,13,14,21]. Aspirated fluid contains a large number of cells, that may consist of neoplastic epithelial cells, activated mesothelial cells and inflammatory cells.…”

Фізіолого-Біохімічний Статус Організму За Умов Розвитку Новоутворень

“…Milevoj еt al., 2019; Mizutani еt al., 2016;Moore, 2014). Незважаючи на величезний об'єм матеріалу, що стосується новоутворень у дрібних тварин, їх етіології, характеру росту, біохімічних процесів, що протікають у пухлинній тканині, не вирішене головне питання: як призупинити ріст новоутворень у хворому організмі(Itoh et al, 2021). Від вміння раннього впізнавання та діагностики і, раннього лікування залежить попередження розповсюдження захворювання, результативність терапії, збереження цінних тварин.…”

Comparison of anti-Müllerian hormone and inhibin immunolabeling in canine and equine granulosa cell tumors

“…1,2 Expression of AMH and inhibin has additionally been evaluated in bovine GCTs, revealing positive immunolabeling for AMH in all GCT cases assessed. 6 Based on these studies, we investigated the potential use of AMH as an IHC marker in the bitch and mare, compared with inhibin immunohistochemistry.…”

“…Although immunohistochemistry is not always necessary in the diagnosis of well-differentiated GCTs, increasing the available panel of IHC markers for these tumors is critical not only to accurately diagnose poorly differentiated GCTs, but also in differentiating such neoplasms from malignant ovarian epithelial tumors. 5,6,8,12 The use of additional markers in poorly differentiated ovarian tumors, such as CK7, has been reported as an accurate means to differentiate ovarian epithelial tumors (positive) from GCTs (negative), especially given that Call-Exner bodies, although fairly specific for GCTs, are not a consistent feature. 9,12 The results that we obtained for AMH correlate with studies conducted in equine and bovine GCTs and suggest that AMH may be used in a broader range of veterinary species for immunohistochemistry studies.…”